We anticipate that Chugai scientists will be able to create a whole range of highly effective "new generation" biologics at a highly accelerated pace. We're impressed with the team at Chugai, and their plans to integrate the ISPRI Toolkit with the OptiMatrix Tool into their antibody engineering and optimization development process. "We have a demonstrated ability to use our immunoinformatics tools to screen and re-engineer protein therapeutics, in federally-funded, peer-reviewed programs (See FVIII, Botulinum toxin, Lysostaphin programs for example) and commercial projects (See partnership with Biotest, AG). "Our unique approach to developing safe and effective protein therapeutics by screening for T effector and T regulatory epitopes (Tregitopes) is at the core of the ISPRI Toolkit," said Anne De Groot, M.D., President and CEO of EpiVax. Tomoyuki Igawa, group manager of Discovery Research Department, of Chugai said, "Integration of ISPRI into the Chugai's antibody engineering and optimization platform will reduce the immunogenicity risk and increase the likelihood of successful clinical development for important, human life-saving biologics." ISPRI is the only screening system that takes into consideration Tregitopes (T regulatory epitopes), a unique EpiVax discovery that is associated with regulatory T cell induction (see website for Tregitope publications).ĭr. is a privately-held and internationally recognized company that specializes in immunogenicity screening for protein therapeutics, immunogenicity mitigation and T cell-driven vaccine design, using a suite of proprietary in silico tools. Researchers at Chugai will be utilizing the cloud-based in silico "Interactive Protein Screening and Reengineering Interface" (ISPRI) in conjunction with OptiMatrix, a tool for deimmunizing biologics, to screen and re-engineer therapeutic proteins for potential immunogenicity and deimmunize immune-dominant epitopes, known as clusters.ĮpiVax, Inc. Consulte la informacin ms completa y actualizada sobre Optimatrix sl: balances, scoring y capacidad mxima de solvencia, CIF B93588069, posibles impagos. Chugai is widely regarded as one of the most cutting edge biopharmaceutical companies in Japan. (Chugai), signed an agreement with Rhode Island-based biotechnology company, EpiVax, Inc., to incorporate EpiVax's ISPRI immunogenicity screening and deimmunization technology into Chugai's drug development toolbox. PROVIDENCE, RI, USA I OctoI Chugai Pharmaceutical Co., Ltd. Developer: (OptiMatrix) Price: (Free) Lists: (0) Points: (77) Version: (2.0) RSS: (+) Track prices.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |